The invention provides a protein degradation targeting BCR-ABL compound as shown in a formula (I) and an application thereof to resisting tumors. The compound as shown in the formula (I) has the effects of degrading and restraining BCR-ABL targeting protein, and mainly consists of four parts of a first part: BCR-ABL-TKIs which is a compound having BCR-ABL tyrosine kinase restraining activity, a second part: LIN which is a link unit, a third part: ULM which is a VHL or CRBN protease micromolecule ligand having a ubiquitination function, and a fourth part: a group A which is carbonyl and is used for performing covalent bonding on the BCR-ABL-TKIs and the LIN and covalent bonding on the LIN and the ULM. A series of compounds designed and synthesized by the invention have broad pharmacological activity, have the functions of degrading BCR-ABL protein and restraining BCR-ABL activity, and can be used for pertinent tumor treatment. (As shown in the description)